Connect your AI

Nektar Therapeutics NKTR Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

Arcus BiosciencesRCUS

$877M-12.7%

Viridian Therapeutics, Inc.VRDN

$586.4M-6.6%

Nuvation BioNUVB

$222.75M-42.0%

AmgenAMGN

——

Spyre Therapeutics, Inc.SYRE

——

Other financials

Income statement

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nektar Therapeutics's available-for-sale debt securities - amortized cost?: Nektar Therapeutics (NKTR) reported available-for-sale debt securities - amortized cost of $695.19M in Q1 2026.
What does available-for-sale debt securities - amortized cost mean?: This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.